# US 2010/0063067 A1 · Cyclic derivatives as modulators of chemokine receptor activity

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0063067 A1
- Document ID: US20100063067A1
- Status: Published application
- Kind: A1
- Application number: 12/444,249
- Filed: 2007-10-03
- Published: 2010-03-11
- Earliest claimed: 2006-10-04
- Assignees: Bristol-Myers Squibb Company
- Inventors: Percy H. Carter; Lyndon A.M. Cornelius
- Web page: https://patentgrep.com/patent/US20100063067A1

## CPC

- C07D 401/14: containing three or more hetero rings
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 17/06: Antipsoriatics
- A61P 19/00: Drugs for skeletal disorders
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/12: Antivirals
- A61P 35/00: Antineoplastic agents
- A61P 37/00: Drugs for immunological or allergic disorders
- C07D 401/06: linked by a carbon chain containing only aliphatic carbon atoms
- C07D 405/14: containing three or more hetero rings
- C07D 417/14: containing three or more hetero rings
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present application describes modulators of MIP-1α of formula (I), or stereoisomers or prodrugs or pharmaceutically acceptable salts thereof, wherein n, A, T, R1, R2 and R8, are as defined herein. In addition, methods of treating and preventing inflammatory diseases such as asthma and allergic diseases, as well as autoimmune pathologies such as rheumatoid arthritis and atherosclerosis using the modulators of formula (I) are disclosed.

## Claims

### Claim 1

A compound of Formula (I):
or stereoisomers or pharmaceutically acceptable salt forms thereof, wherein:
Ring A is
T is a bond,
R1 is aryl, which may be optionally substituted with one or more R1a;
R1a, at each occurrence, is independently selected from alkyl, haloalkyl, alkynyl, halo, —CN, —O(CF2)rCF3, —O(CR8R8)rR10, —OH or —S(CR8R8)rR10;
R2 is aryl, heteroaryl or heterocyclyl, all of which may be optionally substituted with one or more R2a;
R2a, at each occurrence, is independently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl heterocyclylalkyl, halo, —NH2, —CN, —NO2, —C(═O)OH, —C(═O)O(CR8R8)rR10, —O(CF2)rCF3, —O(CR8R8)rR10, —OH, —SH, —S(CR8R8)rR10, —S(O)3H, —P(O)3H2, —C(═O)NR9R9, —NR9R9, —S(O)2NR9R9, —NR9S(O)2(CF2)rCF3, —C(═O)NR9S(O)2R6, —S(O)2NR9C(═O)OR6, —S(O)2NR9C(═O)NR9R9, —C(═O)NR9S(O)2(CF2)rCF3, —C(═O)(CR8R8)rR10, —NR9C(═O)H, —NR9C(═O)(CR8R8)rR10, —NR9C(═O)NR9R9, —OC(═O)(CR8R8)rR10, —C(═NR14)NR9R9, —NHC(═NR14)NR14R14, —S(═O)(CR8R8)rR10, —S(O)2(CR8R8)rR10, —NR9C(═O)OR8, —NR9S(O2)R8, ═O, —S(O)2NR9C(═O)R6, aryloxy or arylalkyl, wherein the alkyl, aryl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl heterocyclylalkyl, aryloxy and arylalkyl may be optionally substituted with one or more R2b;
R2b, at each occurrence, is independently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl heterocyclylalkyl, halo, —NH2, —CN, —NO2, —C(═O)OH, —C(═O)O(CR8R8)rR10, —O(CF2)rCF3, —O(CR8R8)rR10, —OH, —SH, —S(CR8R8)rR10, —S(O)3H, —P(O)3H2, —C(═O)NR9R9, —NR9R9, —S(O)2NR9R9, —NR9S(O)2(CF2)rCF3, —C(═O)NR9S(O)2R6, —S(O)2NR9C(═O)OR6, —S(O)2NR9C(═O)NR9R9, —C(═O)NR9S(O)2(CF2)rCF3, —C(═O)(CR8R8)rR10, —NR9C(═O)H, —NR9C(═O)(CR8R8)rR10, —NR9C(═O)NR9R9, —OC(═O)(CR8R8)rR10, —C(═NR14)NR9R9, —NHC(═NR14)NR14R14, —S(═O)(CR8R8)rR10, —S(O)2(CR8R8)rR10, —NR9C(═O)OR8, —NR9S(O2)R8, aryloxy or arylalkyl;
R3, at each occurrence, is alkyl; or any two R3's attached to the same carbon atom may form a 3- to 5-membered ring;
R4, at each occurrence, is F, alkyl, —OR9 or —NR9R9; or any two alkyl R4's attached to the same carbon atom may form a 3- to 5-membered ring;
R6, at each occurrence, is independently alkyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heteroaryl or heteroarylalkyl;
R8, at each occurrence, is independently hydrogen or alkyl;
R8a, at each occurrence, is independently hydrogen, alkyl or —C(═O)(CR8R8)rR15; or R8a may be taken together with the carbon atom to which it is attached to form a 3- to 6-membered ring wherein the carbon atoms of said ring may be optionally replaced with a heteroatom selected from N, O, and S;
R9, at each occurrence, is independently hydrogen, alkyl, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl or heterocyclylalkyl, wherein the alkyl, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl or heterocyclylalkyl may be optionally substituted with one or more R9a, and the heteroaryl, heteroarylalkyl, heterocyclyl or heterocyclylalkyl contain 1-4 heteroatoms selected from N, O, and S;
R9a, at each occurrence, is independently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl heterocyclylalkyl, halo, —NH2, —CN, —NO2, —C(═O)OH, —C(═O)O(CR8R8)rR14, —O(CF2)rCF3, —O(CR8R8)rR14, —OH, —SH, —S(CR8R8)rR14, —S(O)3H, —P(O)3H2, —C(═O)NR14R14, —NR14R14, —S(O)2NR14R14, —NR14S(O)2(CF2)rCF3, —C(═O)NR14S(O)2R6, —S(O)2NR14C(═O)OR6, —S(O)2NR14C(═O)NR14R14, —C(═O)NR14S(O)2(CF2)rCF3, —C(═O)(CR8R8)rR14, —NR14C(═O)H, —NR14C(═O)(CR8R8)rR14, —OC(═O)(CR8R8)rR14, —C(═NR14)NR14R14, —NHC(═NR14)NR14R14, —S(═O)(CR8R8)rR14, —S(O)2(CR8R8)rR14, —NR14C(═O)OR8, —NR14S(O2)R8, aryloxy or arylalkyl;
R10, at each occurrence, is independently selected from alkyl, cycloalkyl, alkenyl, alkynyl, aryl, arylalkyl, heterocyclyl or heterocyclylalkyl, wherein the alkyl, cycloalkyl, aryl, arylalkyl, heterocyclyl or heterocyclylalkyl may be optionally substituted with one or more R10a, and the heterocyclyl and heterocyclylalkyl contain 1-4 heteroatoms selected from N, O, and S;
R10a, at each occurrence, is independently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl heterocyclylalkyl, halo, —NH2, —CN, —NO2, —C(═O)OH, —C(═O)O(CR8R8)rR14, —O(CF2)rCF3, —O(CR8R8)rR14, —OH, —SH, —S(CR8R8)rR14, —S(O)3H, —P(O)3H2, —C(═O)NR14R14, —NR14R14, —S(O)2NR14R14, —NR14S(O)2(CF2)rCF3, —C(═O)NR14S(O)2R6, —S(O)2NR14C(═O)OR6, —S(O)2NR14C(═O)NR14R14, —C(═O)NR14S(O)2(CF2)rCF3, —C(═O)(CR8R8)rR14, —NR14C(═O)H, —NR14C(═O)(CR8R8)rR14, —OC(═O)(CR8R8)rR14, —C(═NR14)NR14R14, —NHC(═NR14)NR14R14, —S(═O)(CR8R8)rR14, —S(O)2(CR8R8)rR14, —NR14C(═O)OR8, —NR14S(O2)R8, aryloxy or arylalkyl;
R12 is hydrogen, alkyl, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, —S(O)2R15, —C(═O)R15, —C(═O)NH2, —C(═O)NR8R15, —C(═O)OR15 or heterocyclylalkyl, wherein the alkyl, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl or heterocyclylalkyl may be optionally substituted with one or more R12a, and the heteroaryl, heteroarylalkyl, heterocyclyl or heterocyclylalkyl contain 1-4 heteroatoms selected from N, O, and S;
R12a, at each occurrence, is independently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl heterocyclylalkyl, halo, —NH2, —CN, —NO2, —C(═O)OH, —C(═O)O(CR8R8)rR14, —O(CF2)rCF3, —O(CR8R8)rR14, —OH, —SH, —S(CR8R8)rR14, —S(O)3H, —P(O)3H2, —C(═O)NR14R14, —NR14R14, —S(O)2NR14R14, —NR14S(O)2(CF2)rCF3, —C(═O)NR14S(O)2R6, —S(O)2NR14C(═O)OR6, —S(O)2NR14C(═O)NR14R14, —C(═O)NR14S(O)2(CF2)rCF3, —C(═O)(CR8R8)rR14, —NR14C(═O)H, —NR14C(═O)(CR8R8)rR14, —OC(═O)(CR8R8)rR14, —C(═NR14)NR14R14, —NHC(═NR14)NR14R14, —S(═O)(CR8R8)rR14, —S(O)2(CR8R8)rR14, —NR14C(═O)OR8, —NR14S(O2)R8, aryloxy or arylalkyl;
R14, at each occurrence, is independently selected from hydrogen, alkyl, cycloalkyl or phenyl;
R15, at each occurrence, is independently selected from alkyl, cycloalkyl or phenyl, all of which may be optionally substituted with one or more R15a;
R15a, at each occurrence, is independently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl heterocyclylalkyl, halo, —NH2, —CN, —NO2, —C(═O)OH, —C(═O)O(CR8R8)rR14, —O(CF2)rCF3, —O(CR8R8)rR14, —OH, —SH, —S(CR8R8)rR14, —S(O)3H, —P(O)3H2, —C(═O)NR14R14, —NR14R14, —S(O)2NR14R14, —NR14S(O)2(CF2)rCF3, —C(═O)NR14S(O)2R6, —S(O)2NR14C(═O)OR6, —S(O)2NR14C(═O)NR14R14, —C(═O)NR14S(O)2(CF2)rCF3, —C(═O)(CR8R8)rR14, —NR14C(═O)H, —NR14C(═O)(CR8R8)rR14, —OC(═O)(CR8R8)rR14, —C(═NR14)NR14R14, —NHC(═NR14)NR14R14, —S(═O)(CR8R8)rR14, —S(O)2(CR8R8)rR14, —NR14C(═O)OR8, —NR14S(O2)R8, aryloxy or arylalkyl;
m, at each occurrence, is independently 0-2;
n is 1-3;
p is 1 or 2;
q is 0-2; and
r, at each occurrence, is independently 0-5.

### Claim 2 (depends on 1)

The compound of claim 1, or stereoisomers or pharmaceutically acceptable salt forms thereof, wherein the compound is a compound of formula (Ia):

### Claim 3 (depends on 1)

The compound of claim 1, or stereoisomers or pharmaceutically acceptable salt forms thereof, wherein the compound is a compound of formula (Ib):
in which R1 is phenyl optionally substituted with one or more R1a.

### Claim 4 (depends on 1)

The compound of claim 1, or stereoisomers or pharmaceutically acceptable salt forms thereof, wherein
Ring A is
T is
R1 is aryl, which may be optionally substituted with one or more R1a;
R1a, at each occurrence, is independently selected from alkyl, haloalkyl, halo, —CN, —O(CF2)rCF3, —O(CR8R8)rR10, —OH or —S(CR8R8)rR10;
R2 is aryl, heteroaryl or heterocyclyl, all of which may be optionally substituted with one or more R2a;
R2a, at each occurrence, is independently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl heterocyclylalkyl, halo, —NH2, —CN, —NO2, —C(═O)OH, —C(═O)O(CR8R8)rR10, —O(CF2)rCF3, —O(CR8R8)rR10, —OH, —SH, —S(CR8R8)rR10, —S(O)3H, —P(O)3H2, —C(═O)NR9R9, —NR9R9, —S(O)2NR9R9, —NR9S(O)2(CF2)rCF3, —C(═O)NR9S(O)2R6, —S(O)2NR9C(═O)OR6, —S(O)2NR9C(═O)NR9R9, —C(═O)NR9S(O)2(CF2)rCF3, —C(═O)(CR8R8)rR10, —NR9C(═O)H, —NR9C(═O)(CR8R8)rR10, —NR9C(═O)NR9R9, ═O, —S(O)2NR9C(═O)R6, aryloxy or arylalkyl, wherein the alkyl, aryl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl heterocyclylalkyl, aryloxy and arylalkyl may be optionally substituted with one or more R2b;
R2b, at each occurrence, is independently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl heterocyclylalkyl, halo, —NH2, —CN, —NO2, —C(═O)OH, —C(═O)O(CR8R8)rR10, —O(CF2)rCF3, —O(CR8R8)rR10, —OH, —SH, —S(CR8R8)rR10, —S(O)3H, —P(O)3H2, —C(═O)NR9R9, —NR9R9, —S(O)2NR9R9, —NR9S(O)2(CF2)rCF3, —C(═O)NR9S(O)2R6, —S(O)2NR9C(═O)OR6, —S(O)2NR9C(═O)NR9R9, —C(═O)NR9S(O)2(CF2)rCF3, —C(═O)(CR8R8)rR10, —NR9C(═O)H, —NR9C(═O)(CR8R8)rR10, —NR9C(═O)NR9R9, aryloxy or arylalkyl;
R3, at each occurrence, is alkyl; or any two R3's attached to the same carbon atom may form a 3- to 5-membered ring;
R4, at each occurrence, is F, alkyl, —OR9 or —NR9R9; or any two alkyl R4's attached to the same carbon atom may form a 3- to 5-membered ring;
R6, at each occurrence, is independently alkyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heteroaryl or heteroarylalkyl;
R8, at each occurrence, is independently hydrogen or alkyl;
R8a, at each occurrence, is independently hydrogen, alkyl or —C(═O)(CR8R8)rR15;
R9, at each occurrence, is independently hydrogen, alkyl, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl or heterocyclyl, wherein the alkyl, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl or heterocyclyl may be optionally substituted with one or more R9a, and the heteroaryl, heteroarylalkyl, or heterocyclyl contain 1-4 heteroatoms selected from N, O, and S;
R9a, at each occurrence, is independently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl heterocyclylalkyl, halo, —NH2, —CN, —NO2, —C(═O)OH, —C(═O)O(CR8R8)rR14, —O(CF2)rCF3, —O(CR8R8)rR14, —OH, —SH, —S(CR8R8)rR14, —S(O)3H, —P(O)3H2, —C(═O)NR14R14, —NR14R14, —S(O)2NR14R14, —NR14S(O)2(CF2)rCF3, —C(═O)NR14S(O)2R6, —S(O)2NR14C(═O)OR6, —S(O)2NR14C(═O)NR14R14, —C(═O)NR14S(O)2(CF2)rCF3, —C(═O)(CR8R8)rR14, —NR14C(═O)H, —NR14C(═O)(CR8R8)rR14, aryloxy or arylalkyl;
R10, at each occurrence, is independently selected from alkyl, cycloalkyl, alkenyl, alkynyl, aryl, arylalkyl or heterocyclyl, wherein the alkyl, cycloalkyl, aryl, arylalkyl or heterocyclyl may be optionally substituted with one or more R10a, and the heterocyclyl contains 1-4 heteroatoms selected from N, O, and S;
R10a, at each occurrence, is independently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl heterocyclylalkyl, halo, —NH2, —CN, —NO2, —C(═O)OH, —C(═O)O(CR8R8)rR14, —O(CF2)rCF3, —O(CR8R8)rR14, —OH, —SH, —S(CR8R8)rR14, —S(O)3H, —P(O)3H2, —C(═O)NR14R14, —NR14R14, —S(O)2NR14R14, —NR14S(O)2(CF2)rCF3, —C(═O)NR14S(O)2R6, —S(O)2NR14C(═O)OR6, —S(O)2NR14C(═O)NR14R14, —C(═O)NR14S(O)2(CF2)rCF3, —C(═O)(CR8R8)rR14, —NR14C(═O)H, —NR14C(═O)(CR8R8)rR14, aryloxy or arylalkyl;
R12 is hydrogen, alkyl, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, —S(O)2R15, —C(═O)R15, —C(═O)NH2, —C(═O)NR8R15, or —C(═O)OR15, wherein the alkyl, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl or heterocyclyl may be optionally substituted with one or more R12a, and the heteroaryl, heteroarylalkyl or heterocyclyl contain 1-4 heteroatoms selected from N, O, and S;
R12a, at each occurrence, is independently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl heterocyclylalkyl, halo, —NH2, —CN, —NO2, —C(═O)OH, —C(═O)O(CR8R8)rR14, —O(CF2)rCF3, —O(CR8R8)rR14, —OH, —SH, —S(CR8R8)rR14, —S(O)3H, —P(O)3H2, —C(═O)NR14R14, —NR14R14, —S(O)2NR14R14, —NR14S(O)2(CF2)rCF3, —C(═O)NR14S(O)2R6, —S(O)2NR14C(═O)OR6, —S(O)2NR14C(═O)NR14R14, —C(═O)NR14S(O)2(CF2)rCF3, —C(═O)(CR8R8)rR14, —NR14C(═O)H, —NR14C(═O)(CR8R8)rR14, aryloxy or arylalkyl;
R14, at each occurrence, is independently selected from hydrogen, alkyl, cycloalkyl or phenyl;
R15, at each occurrence, is independently selected from alkyl, cycloalkyl or phenyl, all of which may be optionally substituted with one or more R15a;
R15a, at each occurrence, is independently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl heterocyclylalkyl, halo, —NH2, —CN, —NO2, —C(═O)OH, —C(═O)O(CR8R8)rR14, —O(CF2)rCF3, —O(CR8R8)rR14, —OH, —SH, —S(CR8R8)rR14, —S(O)3H, —P(O)3H2, —C(═O)NR14R14, —NR14R14, —S(O)2NR14R14, —NR14S(O)2(CF2)rCF3, —C(═O)NR14S(O)2R6, —S(O)2NR14C(═O)OR6, —S(O)2NR14C(═O)NR14R14, —C(═O)NR14S(O)2(CF2)rCF3, —C(═O)(CR8R8)rR14, —NR14C(═O)H, —NR14C(═O)(CR8R8)rR14, aryloxy or arylalkyl;
m, at each occurrence, is independently 0-2;
n is 1-3;
p is 1 or 2;
q is 0-2; and
r, at each occurrence, is independently 0-5.

### Claim 5 (depends on 1)

The compound of claim 1, or stereoisomers or pharmaceutically acceptable salt forms thereof, wherein
Ring A is
T is
R1 is aryl, which may be optionally substituted with one or more R1a;
R1a, at each occurrence, is independently selected from alkyl, haloalkyl, halo, —CN, —O(CF2)rCF3, —O(CR8R8)rR10 or —OH;
R2 is heteroaryl or heterocyclyl, both of which may be optionally substituted with one or more R2a;
R2a, at each occurrence, is independently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl heterocyclylalkyl, halo, —NH2, —CN, —NO2, —C(═O)OH, —C(═O)O(CR8R8)rR10, —O(CF2)rCF3, —O(CR8R8)rR10, —OH, —SH, —S(CR8R8)rR10, —S(O)3H, —P(O)3H2, —C(═O)NR9R9, —NR9R9, —S(O)2NR9R9, —NR9S(O)2(CF2)rCF3, —C(═O)NR9S(O)2R6, —S(O)2NR9C(═O)OR6, —S(O)2NR9C(═O)NR9R9, —C(═O)NR9S(O)2(CF2)rCF3, ═O, —S(O)2NR9C(═O)R6, aryloxy or arylalkyl, wherein the alkyl, aryl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl heterocyclylalkyl, aryloxy and arylalkyl may be optionally substituted with one or more R2b;
R2b, at each occurrence, is independently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl heterocyclylalkyl, halo, —NH2, —CN, —NO2, —C(═O)OH, —C(═O)O(CR8R8)rR10, —O(CF2)rCF3, —O(CR8R8)rR10, —OH, —SH, —S(CR8R8)rR10, —S(O)3H, —P(O)3H2, —C(═O)NR9R9, —NR9R9, —S(O)2NR9R9, —NR9S(O)2(CF2)rCF3, —C(═O)NR9S(O)2R6, —S(O)2NR9C(═O)OR6, —S(O)2NR9C(═O)NR9R9, —C(═O)NR9S(O)2(CF2)rCF3, aryloxy or arylalkyl;
R3, at each occurrence, is alkyl; or any two R3's attached to the same carbon atom may form a 3- to 5-membered ring;
R4, at each occurrence, is F, alkyl, —OR9 or —NR9R9; or any two alkyl R4's attached to the same carbon atom may form a 3- to 5-membered ring;
R6, at each occurrence, is independently alkyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl or heteroaryl;
R8, at each occurrence, is independently hydrogen or alkyl;
R8a, at each occurrence, is independently hydrogen, alkyl or —C(═O)(CR8R8)rR15;
R9, at each occurrence, is independently hydrogen, alkyl, cycloalkyl, aryl, arylalkyl, heteroaryl or heterocyclyl, wherein the alkyl, cycloalkyl, aryl, arylalkyl, heteroaryl or heterocyclyl may be optionally substituted with one or more R9a, and the heteroaryl or heterocyclyl contain 1-4 heteroatoms selected from N, O, and S;
R9a, at each occurrence, is independently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl heterocyclylalkyl, halo, —NH2, —CN, —NO2, —C(═O)OH, —C(═O)O(CR8R8)rR14, —O(CF2)rCF3, —O(CR8R8)rR14, —OH, —SH, —S(CR8R8)rR14, —S(O)3H, —P(O)3H2, —C(═O)NR14R14, —NR14R14, —S(O)2NR14R14, —NR14S(O)2(CF2)rCF3, —C(═O)NR14S(O)2R6, —S(O)2NR14C(═O)OR6, —S(O)2NR14C(═O)NR14R14, aryloxy or arylalkyl;
R10, at each occurrence, is independently selected from alkyl, cycloalkyl, alkenyl, alkynyl, aryl, arylalkyl or heterocyclyl, wherein the alkyl, cycloalkyl, aryl, arylalkyl or heterocyclyl may be optionally substituted with one or more R10a, and the heterocyclyl contains 1-4 heteroatoms selected from N, O, and S;
R10a, at each occurrence, is independently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl heterocyclylalkyl, halo, —NH2, —CN, —NO2, —C(═O)OH, —C(═O)O(CR8R8)rR14, —O(CF2)rCF3, —O(CR8R8)rR14, —OH, —SH, —S(CR8R8)rR14, —S(O)3H, —P(O)3H2, —C(═O)NR14R14, —NR14R14, —S(O)2NR14R14, —NR14S(O)2(CF2)rCF3, —C(═O)NR14S(O)2R6, —S(O)2NR14C(═O)OR6, —S(O)2NR14C(═O)NR14R14, aryloxy or arylalkyl;
R12 is hydrogen, alkyl, cycloalkyl, aryl, arylalkyl, heteroaryl, heterocyclyl, —S(O)2R15, —C(═O)R15, —C(═O)NH2, —C(═O)NR8R15, or —C(═O)OR15, wherein the alkyl, cycloalkyl, aryl, arylalkyl, heteroaryl or heterocyclyl may be optionally substituted with one or more R12a, and the heteroaryl or heterocyclyl contain 1-4 heteroatoms selected from N, O, and S;
R12a, at each occurrence, is independently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl heterocyclylalkyl, halo, —NH2, —CN, —NO2, —C(═O)OH, —C(═O)O(CR8R8)rR14, —O(CF2)rCF3, —O(CR8R8)rR14, —OH, —SH, —S(CR8R8)rR14, —S(O)3H, —P(O)3H2, —C(═O)NR14R14, —NR14R14, —S(O)2NR14R14, —NR14S(O)2(CF2)rCF3, —C(═O)NR14S(O)2R6, —S(O)2NR14C(═O)OR6, —S(O)2NR14C(═O)NR14R14, aryloxy or arylalkyl;
R14, at each occurrence, is independently selected from hydrogen, alkyl, cycloalkyl or phenyl;
R15, at each occurrence, is independently selected from alkyl, cycloalkyl or phenyl, all of which may be optionally substituted with one or more R15a;
R15a, at each occurrence, is independently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl heterocyclylalkyl, halo, —NH2, —CN, —NO2, —C(═O)OH, —C(═O)O(CR8R8)rR14, —O(CF2)rCF3, —O(CR8R8)rR14, —OH, —SH, —S(CR8R8)rR14, —S(O)3H, —P(O)3H2, —C(═O)NR14R14, —NR14R14, —S(O)2NR14R14, —NR14S(O)2(CF2)rCF3, —C(═O)NR14S(O)2R6, —S(O)2NR14C(═O)OR6, —S(O)2NR14C(═O)NR14R14, aryloxy or arylalkyl;
m, at each occurrence, is independently 0-2;
n is 1-3;
p is 1 or 2;
q is 0-2; and
r, at each occurrence, is independently 0-4.

### Claim 6 (depends on 1)

The compound of claim 1, or stereoisomers or pharmaceutically acceptable salt forms thereof, wherein
Ring A is
T is
R1 is aryl, which may be optionally substituted with one or more R1a;
R1a, at each occurrence, is independently selected from alkyl, haloalkyl, halo, —CN, —O(CR8R8)rR10 or —OH;
R2 is a nitrogen containing heteroaryl or heterocyclyl, both of which may be optionally substituted with one or more R2a;
R2a, at each occurrence, is independently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl heterocyclylalkyl, halo, —NH2, —CN, —NO2, —C(═O)OH, —C(═O)O(CR8R8)rR10, —O(CF2)rCF3, —O(CR8R8)rR10, —OH, —SH, —S(CR8R8)rR10, —S(O)3H, —P(O)3H2, —C(═O)NR9R9, —NR9R9, —S(O)2NR9R9, —NR9S(O)2(CF2)rCF3, —C(═O)NR9S(O)2R6, ═O, aryloxy or arylalkyl, wherein the alkyl, aryl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl heterocyclylalkyl, aryloxy and arylalkyl may be optionally substituted with one or more R2b;
R2b, at each occurrence, is independently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl heterocyclylalkyl, halo, —NH2, —CN, —NO2, —C(═O)OH, —C(═O)O(CR8R8)rR10, —O(CF2)rCF3, —O(CR8R8)rR10, —OH, —SH, —S(CR8R8)rR10, —S(O)3H, —P(O)3H2, —C(═O)NR9R9, —NR9R9, —S(O)2NR9R9, —NR9S(O)2(CF2)rCF3, aryloxy or arylalkyl;
R3, at each occurrence, is alkyl; or any two R3's attached to the same carbon atom may form a 3- to 5-membered ring;
R4, at each occurrence, is F, alkyl, —OR9 or —NR9R9; or any two alkyl R4's attached to the same carbon atom may form a 3- to 5-membered ring;
R6, at each occurrence, is independently alkyl, cycloalkyl, aryl, arylalkyl or heteroaryl;
R8, at each occurrence, is independently hydrogen or alkyl;
R8a, at each occurrence, is independently hydrogen, alkyl or —C(═O)(CR8R8)rR15;
R9, at each occurrence, is independently hydrogen, alkyl, cycloalkyl, aryl, heteroaryl or heterocyclyl, wherein the alkyl, cycloalkyl, aryl, heteroaryl or heterocyclyl may be optionally substituted with one or more R9a, and the heteroaryl or heterocyclyl contain 1-4 heteroatoms selected from N, O, and S;
R9a, at each occurrence, is independently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl heterocyclylalkyl, halo, —NH2, —CN, —NO2, —C(═O)OH, —C(═O)O(CR8R8)rR14, —O(CF2)rCF3, —O(CR8R8)rR14, —OH, —SH, —S(CR8R8)rR14, —S(O)3H, —P(O)3H2, —C(═O)NR14R14, —NR14R14, —S(O)2NR14R14, aryloxy or arylalkyl;
R10, at each occurrence, is independently selected from alkyl, cycloalkyl, alkenyl, aryl, arylalkyl or heterocyclyl, wherein the alkyl, cycloalkyl, aryl, arylalkyl or heterocyclyl may be optionally substituted with one or more R10a, and the heterocyclyl contains 1-4 heteroatoms selected from N, O, and S;
R10a, at each occurrence, is independently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl heterocyclylalkyl, halo, —NH2, —CN, —NO2, —C(═O)OH, —C(═O)O(CR8R8)rR14, —O(CF2)rCF3, —O(CR8R8)rR14, —OH, —SH, —S(CR8R8)rR14, —S(O)3H, —P(O)3H2, —C(═O)NR14R14, —NR14R14, —S(O)2NR14R14, —NR14S(O)2(CF2)rCF3, aryloxy or arylalkyl;
R12 is hydrogen, alkyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, —S(O)2R15, —C(═O)R15, —C(═O)NH2, —C(═O)NR8R15, or —C(═O)OR15, wherein the alkyl, cycloalkyl, aryl, heteroaryl or heterocyclyl may be optionally substituted with one or more R12a, and the heteroaryl or heterocyclyl contain 1-4 heteroatoms selected from N, O, and S;
R12a, at each occurrence, is independently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl heterocyclylalkyl, halo, —NH2, —CN, —NO2, —C(═O)OH, —C(═O)O(CR8R8)rR14, —O(CF2)rCF3, —O(CR8R8)rR14, —OH, —SH, —S(CR8R8)rR14, —S(O)3H, —P(O)3H2, —C(═O)NR14R14, —NR14R14, —S(O)2NR14R14, aryloxy or arylalkyl;
R14, at each occurrence, is independently selected from hydrogen, alkyl, cycloalkyl or phenyl;
R15, at each occurrence, is independently selected from alkyl, cycloalkyl or phenyl, all of which may be optionally substituted with one or more R15a;
R15a, at each occurrence, is independently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl heterocyclylalkyl, halo, —NH2, —CN, —NO2, —C(═O)OH, —C(═O)O(CR8R8)rR14, —O(CF2)rCF3, —O(CR8R8)rR14, —OH, —SH, —S(CR8R8)rR14, —S(O)3H, —P(O)3H2, —C(═O)NR14R14, —NR14R14, —S(O)2NR14R14, aryloxy or arylalkyl;
m, at each occurrence, is independently 0-2;
n is 1-2;
p is 1 or 2;
q is 0-2; and
r, at each occurrence, is independently 0-3.

### Claim 7 (depends on 1)

The compound of claim 1, or stereoisomers or pharmaceutically acceptable salt forms thereof, wherein
Ring A is
T is
R1 is aryl, which may be optionally substituted with one or more R1a;
R1a, at each occurrence, is independently selected from alkyl, halo, —CN, —O(CR8R8)rR10 or —OH;
R2 is a 5- to 10-membered nitrogen containing heteroaryl or heterocyclyl, both of which may be optionally substituted with one or more R2a;
R2a, at each occurrence, is independently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl heterocyclylalkyl, halo, —NH2, —CN, —NO2, —C(═O)OH, —C(═O)O(CR8R8)rR10, —O(CF2)rCF3, —O(CR8R8)rR10, —OH, —SH, —S(CR8R8)rR10, —S(O)3H, —P(O)3H2, —C(═O)NR9R9, —NR9R9, ═O, aryloxy or arylalkyl, wherein the alkyl, aryl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl heterocyclylalkyl, aryloxy and arylalkyl may be optionally substituted with one or more R2b;
R2b, at each occurrence, is independently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl heterocyclylalkyl, halo, —NH2, —CN, —NO2, —C(═O)OH, —C(═O)O(CR8R8)rR10, —O(CF2)rCF3, —O(CR8R8)rR10, —OH, —SH, —S(CR8R8)rR10, —S(O)3H, —P(O)3H2, —C(═O)NR9R9, —NR9R9, aryloxy or arylalkyl;
R3, at each occurrence, is alkyl; or any two R3's attached to the same carbon atom may form a 3- to 5-membered ring;
R4, at each occurrence, is F, alkyl, —OR9 or —NR9R9;
R8, at each occurrence, is independently hydrogen or alkyl;
R8a, at each occurrence, is independently hydrogen, alkyl or —C(═O)(CR8R8)rR15;
R9, at each occurrence, is independently hydrogen, alkyl, cycloalkyl, aryl or heteroaryl, wherein the alkyl, cycloalkyl, aryl or heteroaryl may be optionally substituted with one or more R9a, and the heteroaryl contains 1-4 heteroatoms selected from N, O, and S;
R9a, at each occurrence, is independently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl heterocyclylalkyl, halo, —NH2, —CN, —NO2, —C(═O)OH, —C(═O)O(CR8R8)rR14, —O(CF2)rCF3, —O(CR8R8)rR14, —OH, —SH, —S(CR8R8)rR14, —S(O)3H, —P(O)3H2, —C(═O)NR14R14, —NR14R14, aryloxy or arylalkyl;
R10, at each occurrence, is independently selected from alkyl, cycloalkyl, aryl, arylalkyl or heterocyclyl, wherein the alkyl, cycloalkyl, aryl, arylalkyl or heterocyclyl may be optionally substituted with one or more R10a, and the heterocyclyl contains 1-4 heteroatoms selected from N, O, and S;
R10a, at each occurrence, is independently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl heterocyclylalkyl, halo, —NH2, —CN, —NO2, —C(═O)OH, —C(═O)O(CR8R8)rR14, —O(CF2)rCF3, —O(CR8R8)rR14, —OH, —SH, —S(CR8R8)rR14, —S(O)3H, —P(O)3H2, —C(═O)NR14R14, —NR14R14 aryloxy or arylalkyl;
R12 is hydrogen, alkyl, cycloalkyl, aryl, heteroaryl, —S(O)2R15, —C(═O)R15, —C(═O)NH2, —C(═O)NR8R15, or —C(═O)OR15, wherein the alkyl, cycloalkyl, aryl, or heteroaryl may be optionally substituted with one or more R12a, and the heteroaryl contains 1-4 heteroatoms selected from N, O, and S;
R12a, at each occurrence, is independently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl heterocyclylalkyl, halo, —NH2, —CN, —NO2, —C(═O)OH, —C(═O)O(CR8R8)rR14, —O(CF2)rCF3, —O(CR8R8)rR14, —OH, —SH, —S(CR8R8)rR14, —S(O)3H, —P(O)3H2, —C(═O)NR14R14, —NR14R14, aryloxy or arylalkyl;
R14, at each occurrence, is independently selected from hydrogen, alkyl, cycloalkyl or phenyl;
R15, at each occurrence, is independently selected from alkyl, cycloalkyl or phenyl, all of which may be optionally substituted with one or more R15a;
R15a, at each occurrence, is independently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl heterocyclylalkyl, halo, —NH2, —CN, —NO2, —C(═O)OH, —C(═O)O(CR8R8)rR14, —O(CF2)rCF3, —O(CR8R8)rR14, —OH, —SH, —S(CR8R8)rR14, —S(O)3H, —P(O)3H2, —C(═O)NR14R14, —NR14R14, aryloxy or arylalkyl;
m, at each occurrence, is independently 0-2;
n is 1-2;
q is 0-2; and
r, at each occurrence, is independently 0-2.

### Claim 8 (depends on 1)

The compound of claim 1, or stereoisomers or pharmaceutically acceptable salt forms thereof, wherein
Ring A is
T is
R1 is aryl, which may be optionally substituted with one or more R1a;
R1a, at each occurrence, is independently selected from alkyl, halo, —CN, or —O(CR8R8)rR10;
R2 is a 5- to 8-membered nitrogen containing heteroaryl or heterocyclyl, both of which may be optionally substituted with one or more R2a;
R2a, at each occurrence, is independently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl heterocyclylalkyl, halo, —NH2, —CN, —NO2, —C(═O)OH, —C(═O)O(CR8R8)rR10, —O(CR8R8)rR10, —OH, —SH, —S(CR8R8)rR10, —C(═O)NR9R9, —NR9R9, ═O, aryloxy or arylalkyl, wherein the alkyl, aryl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl heterocyclylalkyl, aryloxy and arylalkyl may be optionally substituted with one or more R2b;
R2b, at each occurrence, is independently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl heterocyclylalkyl, halo, —NH2, —CN, —NO2, —C(═O)OH, —C(═O)O(CR8R8)rR10, —O(CF2)rCF3, —O(CR8R8)rR10, —OH, —SH, —S(CR8R8)rR10, —C(═O)NR9R9, —NR9R9, aryloxy or arylalkyl;
R3, at each occurrence, is alkyl;
R4, at each occurrence, is F, alkyl, —OR9 or —NR9R9;
R8, at each occurrence, is independently hydrogen or alkyl;
R8a, at each occurrence, is independently hydrogen, alkyl or —C(═O)(CR8R8)rR15;
R9, at each occurrence, is independently hydrogen, alkyl, aryl or heteroaryl, wherein the alkyl, aryl or heteroaryl may be optionally substituted with one or more R9a, and the heteroaryl contains 1-4 heteroatoms selected from N, O, and S;
R9a, at each occurrence, is independently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl heterocyclylalkyl, halo, —NH2, —CN, —NO2, —C(═O)OH, —C(═O)O(CR8R8)rR14, —O(CF2)rCF3, —O(CR8R8)rR14, —OH, —SH, —S(CR8R8)rR14, —C(═O)NR14R14, —NR14R14, aryloxy or arylalkyl;
R10, at each occurrence, is independently selected from alkyl, cycloalkyl, aryl or heterocyclyl, wherein the alkyl, cycloalkyl, aryl or heterocyclyl may be optionally substituted with one or more R10a, and the heterocyclyl contains 1-4 heteroatoms selected from N, O, and S;
R10a, at each occurrence, is independently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl heterocyclylalkyl, halo, —NH2, —CN, —NO2, —C(═O)OH, —C(═O)O(CR8R8)rR14, —O(CF2)rCF3, —O(CR8R8)rR14, —OH, —SH, —S(CR8R8)rR14, —C(═O)NR14R14, —NR14R14, aryloxy or arylalkyl;
R12 is hydrogen, alkyl, aryl, heteroaryl, —S(O)2R15, —C(═O)R15, —C(═O)NH2, —C(═O)NR8R15, or —C(═O)OR15, wherein the alkyl, aryl or heteroaryl may be optionally substituted with one or more R12a, and the heteroaryl contains 1-4 heteroatoms selected from N, O, and S;
R12a, at each occurrence, is independently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl heterocyclylalkyl, halo, —NH2, —CN, —NO2, —C(═O)OH, —C(═O)O(CR8R8)rR14, —O(CF2)rCF3, —O(CR8R8)rR14, —OH, —SH, —S(CR8R8)rR14, —C(═O)NR14R14, —NR14R14, aryloxy or arylalkyl;
R14, at each occurrence, is independently selected from hydrogen, alkyl, cycloalkyl or phenyl;
R15, at each occurrence, is independently selected from alkyl, cycloalkyl or phenyl, all of which may be optionally substituted with one or more R15a;
R15a, at each occurrence, is independently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl heterocyclylalkyl, halo, —NH2, —CN, —NO2, —C(═O)OH, —C(═O)O(CR8R8)rR14, —O(CF2)rCF3, —O(CR8R8)rR14, —OH, —SH, —S(CR8R8)rR14, —C(═O)NR14R14, —NR14R14, aryloxy or arylalkyl;
m, at each occurrence, is independently 0-2;
n is 1-2,
q is 0-2; and
r, at each occurrence, is independently 0-2.

### Claim 9 (depends on 1)

The compound of claim 1, or stereoisomers or pharmaceutically acceptable salt forms thereof, wherein
Ring A is
T is
R1 is aryl, which may be optionally substituted with one or more R1a;
R1a, at each occurrence, is independently selected from alkyl, halo, —CN, or —O(CR8R8)rR10;
R2 is a 5- to 8-membered nitrogen containing heteroaryl or heterocyclyl, both of which may be optionally substituted with one or more R2a and wherein the 5- to 8-membered nitrogen containing heteroaryl or heterocyclyl is attached via a nitrogen heteroatom;
R2a, at each occurrence, is independently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, heteroaryl, heterocyclyl, halo, —NH2, —CN, —NO2, —C(═O)OH, —C(═O)O(CR8R8)rR10, —O(CR8R8)rR10, —OH, —SH, —S(CR8R8)rR10, —C(═O)NR9R9, —NR9R9, ═O or aryloxy, wherein the alkyl, aryl, cycloalkyl, heteroaryl, heterocyclyl and aryloxy may be optionally substituted with one or more R2b;
R2b, at each occurrence, is independently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl heterocyclylalkyl, halo, —NH2, —CN, —NO2, —C(═O)OH, —C(═O)O(CR8R8)rR10, —O(CR8R8)rR10, —OH, —SH, —NR9R9, aryloxy or arylalkyl;
R3, at each occurrence, is alkyl;
R4, at each occurrence, is F, alkyl, —OR9 or NR9R9;
R8, at each occurrence, is independently hydrogen or alkyl;
R8a, at each occurrence, is independently hydrogen, alkyl or —C(═O)(CR8R8)rR15;
R9, at each occurrence, is independently hydrogen, alkyl or aryl, wherein the alkyl or aryl may be optionally substituted with one or more R9a;
R9a, at each occurrence, is independently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, heteroaryl, heterocyclyl, halo, —NH2, —CN, —NO2, —C(═O)OH, —C(═O)O(CR8R8)rR14, —O(CF2)rCF3, —O(CR8R8)rR14, —OH, —SH, —S(CR8R8)rR14, —C(═O)NR14R14, —NR14R14 or aryloxy;
R10, at each occurrence, is independently selected from alkyl, aryl or heterocyclyl, wherein the alkyl, aryl or heterocyclyl may be optionally substituted with one or more R10a, and the heterocyclyl contains 1-4 heteroatoms selected from N, O, and S;
R10a, at each occurrence, is independently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, heteroaryl, heterocyclyl, halo, —NH2, —CN, —NO2, —C(═O)OH, —C(═O)O(CR8R8)rR14, —O(CF2)rCF3, —O(CR8R8)rR14, —OH, —SH, —S(CR8R8)rR14, —C(═O)NR14R14, —NR14R14 or aryloxy;
R12 is hydrogen, alkyl, heteroaryl, —S(O)2R15, —C(═O)R15, —C(═O)NH2, —C(═O)NR8R15, or —C(═O)OR15, wherein the alkyl or heteroaryl may be optionally substituted with one or more R12a, and the heteroaryl contains 1-4 heteroatoms selected from N, O, and S;
R12a, at each occurrence, is independently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, heteroaryl, heterocyclyl, halo, —NH2, —CN, —NO2, —C(═O)OH, —C(═O)O(CR8R8)rR14, —O(CF2)rCF3, —O(CR8R8)rR14, —OH, —SH, —S(CR8R8)rR14, —C(═O)NR14R14, —NR14R14 or aryloxy;
R14, at each occurrence, is independently selected from hydrogen, alkyl, cycloalkyl or phenyl;
R15, at each occurrence, is independently selected from alkyl, cycloalkyl or phenyl, all of which may be optionally substituted with one or more R15a;
R15a, at each occurrence, is independently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, heteroaryl, heterocyclyl, halo, —NH2, —CN, —NO2, —C(═O)OH, —C(═O)O(CR8R8)rR14, —O(CF2)rCF3, —O(CR8R8)rR14, —OH, —SH, —S(CR8R8)rR14, —C(═O)NR14R14, —NR14R14 or aryloxy;
m, at each occurrence, is independently 0-2;
n is 1-2;
q is 1 or 2; and
r, at each occurrence, is independently 0-2.

### Claim 10 (depends on 1)

The compound of claim 1, or stereoisomers or pharmaceutically acceptable salt forms thereof, wherein
Ring A is
T is
R1 is aryl, which may be optionally substituted with one or more R1a;
R1a, at each occurrence, is independently selected from halo, —CN, or —O(CR8R8)rR10;
R2 is a 5- to 8-membered nitrogen containing heteroaryl or heterocyclyl, both of which may be optionally substituted with one or more R2a and wherein the 5- to 8-membered nitrogen containing heteroaryl or heterocyclyl is attached via a nitrogen heteroatom;
R2a, at each occurrence, is independently selected from alkyl, haloalkyl, aryl, cycloalkyl, heteroaryl, heterocyclyl, halo, —NH2, —CN, —NO2, —C(═O)OH, —C(═O)O(CR8R8)rR10, —O(CR8R8)rR10, —OH, —SH, —S(CR8R8)rR10, —C(═O)NR9R9, —NR9R9 or ═O, wherein the alkyl, aryl, cycloalkyl, heteroaryl, heterocyclyl and aryloxy may be optionally substituted with one or more R2b;
R2b, at each occurrence, is independently selected from alkyl, haloalkyl, aryl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl heterocyclylalkyl, halo, —NH2, —CN, —NO2, —C(═O)OH, —C(═O)O(CR8R8)rR10, —O(CR8R8)rR10, —OH, —SH, or —NR9R9;
R3 is alkyl;
R4, at each occurrence, is F, alkyl or —OR9;
R8, at each occurrence, is independently hydrogen or alkyl;
R8a, at each occurrence, is independently hydrogen, alkyl or —C(═O)(CR8R8)rR15;
R9, at each occurrence, is independently hydrogen, alkyl or aryl, wherein the alkyl or aryl may be optionally substituted with one or more R9a;
R9a, at each occurrence, is independently selected from alkyl, haloalkyl, aryl, cycloalkyl, heteroaryl, heterocyclyl, halo, —NH2, —CN, —NO2, —C(═O)OH, —C(═O)O(CR8R8)rR14, —O(CF2)rCF3, —O(CR8R8)rR14, —OH, —SH, —S(CR8R8)rR14, —C(═O)NR14R14 or —NR14R14;
R10, at each occurrence, is independently selected from alkyl or aryl, wherein the alkyl or aryl may be optionally substituted with one or more R10a;
R10a, at each occurrence, is independently selected from alkyl, haloalkyl, aryl, cycloalkyl, heteroaryl, heterocyclyl, halo, —NH2, —CN, —NO2, —C(═O)OH, —C(═O)O(CR8R8)rR14, —O(CF2)rCF3, —O(CR8R8)rR14, —OH, —SH, —S(CR8R8)rR14, —C(═O)NR14R14 or —NR14R14;
R12 is hydrogen, alkyl, heteroaryl, —S(O)2R15, —C(═O)R15, —C(═O)NH2, —C(═O)NR8R15, or —C(═O)OR15, wherein the alkyl or heteroaryl may be optionally substituted with one or more R12a, and the heteroaryl contains 1-4 heteroatoms selected from N, O, and S;
R12a, at each occurrence, is independently selected from alkyl, haloalkyl, aryl, cycloalkyl, heteroaryl, heterocyclyl, halo, —NH2, —CN, —NO2, —C(═O)OH, —C(═O)O(CR8R8)rR14, —O(CF2)rCF3, —O(CR8R8)rR14, —OH, —SH, —S(CR8R8)rR14, —C(═O)NR14R14 or —NR14R14;
R14, at each occurrence, is independently selected from hydrogen, alkyl, cycloalkyl or phenyl;
R15, at each occurrence, is independently selected from alkyl, cycloalkyl or phenyl, all of which may be optionally substituted with one or more R15a;
R15a, at each occurrence, is independently selected from alkyl, haloalkyl, aryl, cycloalkyl, heteroaryl, heterocyclyl, halo, —NH2, —CN, —NO2, —C(═O)OH, —C(═O)O(CR8R8)rR14, —O(CF2)rCF3, —O(CR8R8)rR14, —OH, —SH, —S(CR8R8)rR14, —C(═O)NR14R14 or —NR14R14;
m, at each occurrence, is independently 0-2;
n is 1-2;
q is 1 or 2; and
r, at each occurrence, is independently 0-2.

### Claim 11 (depends on 1)

The compound of claim 1, or stereoisomers or pharmaceutically acceptable salt forms thereof, wherein
Ring A
T is
R1 is phenyl, which may be optionally substituted with one or more R1a;
R1a, at each occurrence, is independently selected from halo, —CN, or —O(CR8R8)rR10;
R2 is a 5- to 8-membered nitrogen containing heteroaryl or heterocyclyl, both of which may be optionally substituted with one or more R2a and wherein the 5- to 8-membered nitrogen containing heteroaryl or heterocyclyl is attached via a nitrogen heteroatom;
R2a, at each occurrence, is independently selected from alkyl, haloalkyl, aryl, cycloalkyl, heteroaryl, heterocyclyl, halo, —NH2, —CN, —NO2, —C(═O)OH, —C(═O)O(CR8R8)rR10, —O(CR8R8)rR10, —OH, —C(═O)NR9R9, —NR9R9 or ═O, wherein the alkyl, aryl, cycloalkyl, heteroaryl, heterocyclyl and aryloxy may be optionally substituted with one or more R2b;
R2b, at each occurrence, is independently selected from alkyl, haloalkyl, aryl, cycloalkyl, heteroaryl, heterocyclyl, halo, —NH2, —CN, —NO2, —C(═O)OH, —C(═O)O(CR8R8)rR10, —O(CR8R8)rR10, —OH, —SH, or —NR9R9;
R3 is alkyl;
R4, at each occurrence, is alkyl or —OR9;
R8, at each occurrence, is independently hydrogen or alkyl;
R8a, at each occurrence, is independently hydrogen, alkyl or —C(═O)(CR8R8)rR15;
R9, at each occurrence, is independently hydrogen, alkyl or aryl, wherein the alkyl or aryl may be optionally substituted with one or more R9a;
R9a, at each occurrence, is independently selected from alkyl, haloalkyl, aryl, cycloalkyl, heteroaryl, heterocyclyl, halo, —NH2, —CN, —NO2, —C(═O)OH, —C(═O)O(CR8R8)rR14, —O(CF2)rCF3, —O(CR8R8)rR14, —OH, —C(═O)NR14R14 or —NR14R14;
R10, at each occurrence, is independently selected from alkyl or aryl, wherein the alkyl or aryl may be optionally substituted with one or more R10a;
R10a, at each occurrence, is independently selected from alkyl, haloalkyl, aryl, cycloalkyl, heteroaryl, heterocyclyl, halo, —NH2, —CN, —NO2, —C(═O)OH, —C(═O)O(CR8R8)rR14, —O(CF2)rCF3, —O(CR8R8)rR14, —OH, —C(═O)NR14R14 or —NR14R14;
R12 is alkyl, heteroaryl, —S(O)2R15, —C(═O)R15, —C(═O)NH2, —C(═O)NR8R15, or —C(═O)OR15, wherein the alkyl or heteroaryl may be optionally substituted with one or more R12a, and the heteroaryl contains 1-4 heteroatoms selected from N, O, and S;
R12a, at each occurrence, is independently selected from alkyl, haloalkyl, aryl, cycloalkyl, heteroaryl, heterocyclyl, halo, —NH2, —CN, —NO2, —C(═O)OH, —C(═O)O(CR8R8)rR14, —O(CF2)rCF3, —O(CR8R8)rR14, —OH, —C(═O)NR14R14 or —NR14R14;
R14, at each occurrence, is independently selected from hydrogen, alkyl, cycloalkyl or phenyl;
R15, at each occurrence, is independently selected from alkyl, cycloalkyl or phenyl, all of which may be optionally substituted with one or more R15a;
R15a, at each occurrence, is independently selected from alkyl, haloalkyl, aryl, cycloalkyl, heteroaryl, heterocyclyl, halo, —NH2, —CN, —NO2, —C(═O)OH, —C(═O)O(CR8R8)rR14, —O(CF2)rCF3, —O(CR8R8)rR14, —OH, —C(═O)NR14R14 or —NR14R14;
m, at each occurrence, is independently 0-2;
n is 1-2; and
r, at each occurrence, is independently 0-2.

### Claim 12 (depends on 1)

The compound of claim 1, or stereoisomers or pharmaceutically acceptable salt forms thereof, wherein
Ring A is
T is
R1 is phenyl, which may be optionally substituted with one or more R1a;
R1a, at each occurrence, is independently selected from halo, —CN, or —O(CR8R8)rR10;
R2 is a 5- to 8-membered nitrogen containing heteroaryl or heterocyclyl, both of which may be optionally substituted with one or more R2a and wherein the 5- to 8-membered nitrogen containing heteroaryl or heterocyclyl is attached via a nitrogen heteroatom;
R2a, at each occurrence, is independently selected from alkyl, haloalkyl, aryl, cycloalkyl, heteroaryl, heterocyclyl, halo, —NH2, —CN, —NO2, —C(═O)OH, —C(═O)O(CR8R8)rR10, —O(CR8R8)rR10, —OH or ═O, wherein the alkyl, aryl, cycloalkyl, heteroaryl, heterocyclyl and aryloxy may be optionally substituted with one or more R2b;
R2b, at each occurrence, is independently selected from alkyl, haloalkyl, aryl, cycloalkyl, heteroaryl, heterocyclyl, halo, —NH2, —CN, —NO2, —C(═O)OH, —C(═O)O(CR8R8)rR10, —O(CR8R8)rR10, or —OH;
R3 is alkyl;
R8, at each occurrence, is independently hydrogen or alkyl;
R8a, at each occurrence, is independently hydrogen, alkyl or —C(═O)(CR8R8)rR15;
R10, at each occurrence, is independently selected from alkyl or aryl, wherein the alkyl or aryl may be optionally substituted with one or more R10a;
R10a, at each occurrence, is independently selected from alkyl, haloalkyl, aryl, cycloalkyl, heteroaryl, heterocyclyl, halo, —NH2, —CN, —NO2, —C(═O)OH, —C(═O)O(CR8R8)rR14; —O(CR8R8)rR14; —OH, —C(═O)NR14R14 or —NR14R14;
R12 is alkyl, heteroaryl, —S(O)2R15, —C(═O)R15, —C(═O)NH2, —C(═O)NR8R15, or —C(═O)OR15, wherein the alkyl or heteroaryl may be optionally substituted with one or more R12a, and the heteroaryl contains 1-4 heteroatoms selected from N, O, and S;
R12a, at each occurrence, is independently selected from alkyl, haloalkyl, aryl, cycloalkyl, heteroaryl, heterocyclyl, halo, —NH2, —CN, —NO2, —C(═O)OH, —C(═O)O(CR8R8)rR14; —O(CR8R8)rR14, —OH, —C(═O)NR14R14 or —NR14R14;
R14, at each occurrence, is independently selected from hydrogen, alkyl, cycloalkyl or phenyl;
R15, at each occurrence, is independently selected from alkyl, cycloalkyl or phenyl, all of which may be optionally substituted with one or more R15a;
R15a, at each occurrence, is independently selected from alkyl, haloalkyl, aryl, cycloalkyl, heteroaryl, heterocyclyl, halo, —NH2, —CN, —NO2, —C(═O)OH, —C(═O)O(CR8R8)rR14; —O(CR8R8)rR14, —OH, or —NR14R14;
m, at each occurrence, is independently 0-2;
n is 1-2; and
r, at each occurrence, is independently 0 or 1.

### Claim 13 (depends on 1)

The compound of claim 1, or stereoisomers or pharmaceutically acceptable salt forms thereof, wherein
Ring A is
T is
R1 is phenyl, which may be optionally substituted with one or more R1a;
R1a, at each occurrence, is independently selected from halo, —CN, or —O(CR8R8)rR10;
R2 is pyrazolyl, imidazolyl, indolyl, tetrazolyl, triazolyl, benzoimidazolyl, pyridinyl, imidazopyridinyl, dihydro-benzoimidazolyl, pyrazolopyridinyl, pyridinonyl, pyrimidinonylor pyrimidinyl, all of which may be optionally substituted with one or more R2a and wherein pyrazolyl, imidazolyl, indolyl, tetrazolyl, triazolyl, benzoimidazolyl, pyridinyl, imidazopyridinyl, dihydro-benzoimidazolyl, pyrazolopyridinyl, pyridinonyl, pyrimidinonylor pyrimidinyl is attached via a nitrogen heteroatom;
R2a, at each occurrence, is independently selected from alkyl, haloalkyl, aryl, cycloalkyl, heteroaryl, heterocyclyl, halo, —NH2, —CN, —NO2, —C(═O)OH, —C(═O)O(CR8R8)rR10, —O(CR8R8)rR10, —OH or ═O;
R3 is alkyl;
R8, at each occurrence, is independently hydrogen or alkyl;
R8a, at each occurrence, is independently hydrogen, alkyl or —C(═O)(CR8R8)rR15;
R10, at each occurrence, is independently selected from alkyl or aryl, wherein the alkyl or aryl may be optionally substituted with one or more R10a;
R10a, at each occurrence, is independently selected from alkyl, haloalkyl, aryl, cycloalkyl, heteroaryl, heterocyclyl, halo, —NH2, —CN, —O(CR8R8)rR14, —OH, —C(═O)NR14R14 or —NR14R14;
R12 is alkyl, heteroaryl, —S(O)2R15, —C(═O)R15, —C(═O)NH2, —C(═O)NR8R15, or —C(═O)OR15, wherein the alkyl or heteroaryl may be optionally substituted with one or more R12a, and the heteroaryl contains 1-4 heteroatoms selected from N, O, and S;
R12a, at each occurrence, is independently selected from alkyl, haloalkyl, aryl, cycloalkyl, heteroaryl, heterocyclyl, halo, —NH2, —CN, —O(CR8R8)rR14, —OH, —C(═O)NR14R14 or —NR14R14;
R14, at each occurrence, is independently selected from hydrogen, alkyl, cycloalkyl or phenyl;
R15, at each occurrence, is independently selected from alkyl, cycloalkyl or phenyl, all of which may be optionally substituted with one or more R15a;
R15a, at each occurrence, is independently selected from alkyl, haloalkyl, aryl, cycloalkyl, heteroaryl, heterocyclyl, halo, —NH2, —CN, —O(CR8R8)rR14, —OH, or —NR14R14;
m, at each occurrence, is independently 0-2;
n is 1-2; and
r, at each occurrence, is independently 0 or 1.

### Claim 14 (depends on 1)

A pharmaceutical composition comprised of a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of claim 1.

### Claim 15 (depends on 1)

Use of at least one compound of claim 1 in the manufacture of a medicament for modulating chemokine or chemokine receptor activity or treating a disorder comprising administering to a patient in need; wherein said disorder is selected from osteoarthritis, aneurysm, fever, cardiovascular effects, Crohn's disease, congestive heart failure, autoimmune diseases, HIV-infection, HIV-associated dementia, psoriasis, idiopathic pulmonary fibrosis, transplant arteriosclerosis, physically- or chemically-induced brain trauma, inflammatory bowel disease, alveolitis, colitis, systemic lupus erythematosus, nephrotoxic serum nephritis, glomerularnephritis, asthma, multiple sclerosis, atherosclerosis, rheumatoid arthritis, restinosis, organ transplantation, and cancer.
